Treatment of cirrhotic of liver

Evaluation of autologous bone marrow stem cells transfusion in treatment of cirrhotic, in decompensated cirrhotic patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014091919217N1

Enrollment

Registered

2014-10-23

Start date

2014-11-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhotic of liver. Chronic passive congestion of liver

Interventions

Intervention 1: Intervention group: Stem cells (120-200 CC) are injected in patients with liver cirrhosis, using special filters to collect fat particles, possible clots and other particles during one

Treatment - Other

Intervention group: Stem cells (120-200 CC) are injected in patients with liver cirrhosis, using special filters to collect fat particles, possible clots and other particles during one hour.

Control group: Patients with liver cirrhosis, not receiving stem cells, were allocated to the control group.

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age range of 18 to 60 years; Having cirrhosis, based on clinical symptoms and laboratory, endoscopic and radiological findings; Being a candidate for liver transplant. Exclusion criteria: Concurrent diseases such as heart, kidney, and pulmonary conditions; Presence of a hepatic mass indicating hepatocellular carcinoma, according to radiological findings; Extrahepatic malignancies; Moderate to severe hepatic encephalopathy; HIV positive; Presence of malignancies; Activated hepatic vein thrombosis, spleen and portal venous; Concurrent extrahepatic infections; Active venous bleeding; History of alcohol consumption; Lack of patient’s consent

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
MELD score. Timepoint: Every week after the intervention for two weeks. Method of measurement: Calculating by algorithm formula.;Laboratory tests (albumin, hemoglobin and blood clotting tests). Timepoint: once a week after the intervention for a period of two week. Method of measurement: Blood test.;Child score. Timepoint: Every week after the intervention for two weeks. Method of measurement: Calculating by algorithm formula.	—

Measure

Time frame

MELD score. Timepoint: Every week after the intervention for two weeks. Method of measurement: Calculating by algorithm formula.;Laboratory tests (albumin, hemoglobin and blood clotting tests). Timepoint: once a week after the intervention for a period of two week. Method of measurement: Blood test.;Child score. Timepoint: Every week after the intervention for two weeks. Method of measurement: Calculating by algorithm formula.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHomeira Omati

Mashhad University of Medical Sciences

internist_omati@yahoo.com+98 51 3846 2388

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 20, 2026